Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of 552-02 Free Base. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 552-02 Free Base SCHEMBL15092803 | 1.00 | SCNN1A (0.67) | SCNN1AKCNH2 | |
| 552-02 Free Base SCHEMBL9913757 | 0.97 | SCNN1A (0.71) | SCNN1A | |
| 552-02 Free Base SCHEMBL2015162 | 0.97 | SCNN1A (0.71) | SCNN1A | |
| 552-02 Free Base SCHEMBL9913774 | 0.97 | SCNN1A (0.71) | SCNN1A | |
| 552-02 Free Base SCHEMBL19348088 | 0.96 | SCNN1A (0.70) | SCNN1A | |
| SCHEMBL916347 | 0.94 | SCNN1A (0.67) | SCNN1A | |
| SCHEMBL14268270 | 0.91 | SCNN1A (0.60) | SCNN1AKCNH2 | |
| SCHEMBL10028716 | 0.91 | SCNN1A (0.60) | SCNN1AKCNH2 | |
| SCHEMBL14268271 | 0.91 | SCNN1A (0.60) | SCNN1AKCNH2 | |
| SCHEMBL10110701 | 0.90 | SCNN1A (0.62) | SCNN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713056-A1 | DEVICE FOR PROVIDING CONTINUED BREATH GUIDANCE, METHOD OF OPERATING AN INHALATION DEVICE, INHALATION DEVICE AND INHALATION DEVICE SYSTEM FOR PROVIDING INHALATION PROCESS/BREATH GUIDING | Pari Medical Holding GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712837-A1 | METHOD OF OPERATING AN INHALATION DEVICE, INHALATION DEVICE, INHALATION DEVICE SYSTEM FOR PROVIDING INHALATION PROCESS FEEDBACK AND DEVICE FOR PROVIDING FEEDBACK GUIDANCE | Pari Medical Holding GmbH (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-12544520-B2 | Aerosol delivery device and method of operating the aerosol delivery device | PARI PHARMA GMBH (DE) | 2026-02-10 | — | — | US | disclosed |
| EP-4659255-A1 | MEDICAL EVALUATION METHOD, AEROSOL NEBULIZER AND MEDICAL EVALUATION SYSTEM | Pari Medical Holding GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024236034-A1 | DEVICE FOR PROVIDING CONTINUED BREATH GUIDANCE, METHOD OF OPERATING AN INHALATION DEVICE, INHALATION DEVICE AND INHALATION DEVICE SYSTEM FOR PROVIDING INHALATION PROCESS/BREATH GUIDING | PARI MEDICAL HOLDING GMBH (DE) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024236057-A1 | METHOD OF OPERATING AN INHALATION DEVICE, INHALATION DEVICE, INHALATION DEVICE SYSTEM FOR PROVIDING INHALATION PROCESS FEEDBACK AND DEVICE FOR PROVIDING FEEDBACK GUIDANCE | PARI MEDICAL HOLDING GMBH (DE) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024160951-A1 | MEDICAL EVALUATION METHOD, AEROSOL NEBULIZER AND MEDICAL EVALUATION SYSTEM | PARI MEDICAL HOLDING GMBH (DE) | 2024-08-08 | — | — | WO | disclosed |
| EP-4259607-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2023-10-18 | — | — | EP | disclosed |
| EP-4082023-A1 | CONTROL DEVICE FOR AEROSOL NEBULIZER SYSTEM | PARI Pharma GmbH (DE) | 2022-11-02 | — | — | EP | disclosed |
| WO-2022123314-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2022-06-16 | — | — | WO | disclosed |
| CN-110214141-B | Benzodiazolium compounds as ENaC inhibitors | 企业治疗学有限公司 | 2022-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544520-B2 | Aerosol delivery device and method of operating the aerosol delivery device | VAPA, VAPB, PIEZO1 | SCNN1A 452/4885KCNH2 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.